Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Bryce

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancerMadeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Gynecologic Oncology|February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancerFelicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trialsMassimo Di Maio, Ciro Gallo, Natasha B Leighl, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovaryAikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, et al.
Seminars in Oncology|December 18, 2017
Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer PatientsEttore Capoluongo, Gillian Ellison, José Antonio López-Guerrero, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 23, 2020
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare systemSilvia Riva, Fabio Efficace, Massimo Di Maio, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit StudyYeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Gynecologic Oncology|June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancerRachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 8, 2015
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapiesAlexandre Chan, Michael C Cameron, Benjamin Garden, et al.
BMJ Open|October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare systemSilvia Riva, Laura Arenare, Massimo Di Maio, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancerMadeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Gynecologic Oncology|February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancerFelicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trialsMassimo Di Maio, Ciro Gallo, Natasha B Leighl, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovaryAikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, et al.
Seminars in Oncology|December 18, 2017
Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer PatientsEttore Capoluongo, Gillian Ellison, José Antonio López-Guerrero, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 23, 2020
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare systemSilvia Riva, Fabio Efficace, Massimo Di Maio, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit StudyYeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Gynecologic Oncology|June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancerRachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 8, 2015
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapiesAlexandre Chan, Michael C Cameron, Benjamin Garden, et al.
BMJ Open|October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare systemSilvia Riva, Laura Arenare, Massimo Di Maio, et al.
Pageof 4